VTv Therapeutics Ownership
| VTVT Stock | USD 14.66 0.41 2.88% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 6.4 M | Current Value 5.5 M | Avarage Shares Outstanding 2.7 M | Quarterly Volatility 3.3 M |
VTv |
VTv Stock Ownership Analysis
About 39.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 4.37. vTv Therapeutics had not issued any dividends in recent years. The entity had 1:40 split on the 21st of November 2023. vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews Forbes Incorporated. Vtv Theraptcs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more information please call Paul MSc at 336 841 0300 or visit https://vtvtherapeutics.com.VTv Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VTv Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading vTv Therapeutics backward and forwards among themselves. VTv Therapeutics' institutional investor refers to the entity that pools money to purchase VTv Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-09-30 | 178 | Activest Wealth Management | 2024-09-30 | 50.0 | Parallel Advisors, Llc | 2024-09-30 | 38.0 | Planned Solutions, Inc. | 2024-09-30 | 25.0 | Cornerstone Planning Group Llc | 2024-09-30 | 19.0 | Sunbelt Securities | 2024-09-30 | 15.0 | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 9.0 | Bank Of America Corp | 2024-09-30 | 8.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Samsara Biocapital, Llc | 2024-09-30 | 206.8 K | Fmr Inc | 2024-09-30 | 178.2 K |
vTv Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VTv Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VTv Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VTv Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VTv Therapeutics Outstanding Bonds
VTv Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. vTv Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VTv bonds can be classified according to their maturity, which is the date when vTv Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Viking Cruises Ltd Corp BondUS91832VAA26 | View | |
| US91835HAA05 Corp BondUS91835HAA05 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
VTv Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 23rd of September 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.